Minimally Invasive Biopsy Technologies Market Size to Reach 3.98 Billion in 2027 | Industry Trend – Rapid Advancements in Biopsy Techniques

High prevalence of cancer across the globe, improving healthcare infrastructure, and increasing healthcare spending are some key factors expected to fuel market revenue growth

 

Emergen Research has published its latest report titled, “Minimally Invasive Biopsy Technologies Market By Technology (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Breath Biopsy, Others), By Therapeutic Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Blood Cancer, Non-oncology Applications), By End Use and Region Forecasts to 2027”

 

According to Emergen Research, the global minimally invasive biopsy technologies market size was USD 1.08 billion in 2019 and is expected to reach USD 3.98 billion in 2027 and register a robust revenue CAGR of 17.6% during the forecast period, 2020-2027.

 

Market Dynamics: 

A minimally invasive biopsy is a procedure that uses fine needles attached to a vacuum device to extract cells and tissue samples.  Minimally invasive biopsy techniques have proven to be essential for acquiring accurate diagnosis of tumor cells over the years. According to World Health Organization, cancer is one of the leading causes of death across the globe. These procedures are rapidly gaining traction owing to increasing preference for minimally invasive surgeries and rising demand for advanced biopsy techniques. Factors such as rising prevalence of lung cancer, breast cancer, prostate cancer, colorectal cancer, and blood cancer across the globe, increasing awareness about early diagnosis and treatment, and increasing adoption of advanced biopsy techniques in hospitals and ambulatory surgical centers worldwide are expected to fuel market growth during the forecast period.

Click Here to Access Free sample PDF Copy of the Report@ https://www.emergenresearch.com/request-sample/75

In addition, increasing focus on developing advanced products, rising adoption of liquid and optical biopsies, and rising investments in research and development activities are expected to fuel market growth going ahead. However, high cost of treatment and biopsy technologies, lower sensitivity of some liquid biopsies, lack of adequate reimbursement scenarios, and stringent regulatory norms are some key factors expected to hamper global market growth to a certain extent during the forecast period.

 

COVID-19 Impact Analysis 

  • Social distancing and restrictions severely disrupted businesses and operations
  • Lockdowns caused disruptions in transportation and logistics
  • Impacted manufacturing activities and mining operations globally
  • Took a toll on economy of various countries
  • Caused sudden and drastic downturn in economic activity
  • Disrupted agriculture, fisheries, dairy, and other sectors
  • Caused loss of employment and financial crisis
  • Supply impacts were further compounded owing to reduced disposable income
  • Emergence of variants continue to cause concerns and impact normal routines

Breast Cancer Segment to Account for Largest Revenue Share:

 

The breast cancer segment is expected to account for significant revenue share over the forecast period. This can be attributed to factors including increasing prevalence of breast cancer, increasing public awareness about early diagnosis and treatment, rapid advancements in biopsy techniques, and increasing adoption of minimally invasive breast biopsy techniques across medium to large scale hospitals and ambulatory care centers.

 

Liquid Biopsy Segment to Register Rapid Revenue Growth:

 

The liquid biopsy segment is expected to register rapid revenue growth during the forecast period owing to increasing prevalence of cancer across the globe, high preference for minimally invasive treatment procedures, and availability of advanced liquid biopsy tests, kits, and equipment.

Looking for Discount [Click on the link] @ https://www.emergenresearch.com/request-discount/75

 

North America to Lead In Terms of Revenue:

 

North America is expected to account for largest revenue share in the global market between 2020 and 2027 owing to factors such as high prevalence of various types of cancer across the region, increasing demand for minimally invasive techniques, and presence of well-established healthcare facilities. Other factors driving market revenue growth in North America are increasing number of ambulatory surgical centers, rising awareness about early diagnosis and treatment, and increasing investments in research and development activities.

 

Major Companies in the Market Include:

  • Chronix Biomedical
  • Biocept, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mauna Kea Technologies
  • Veracyte, Inc.
  • Thermo Fisher Scientific
  • NeoGenomics Laboratories, Inc.
  • Abcodia Ltd.
  • Adaptive Biotechnologies
  • Owlstone Medical Ltd.

Have a look at Report Description and Table of Contents of Market Report@ https://www.emergenresearch.com/industry-report/minimally-invasive-biopsy-technologies-market

For the purpose of this report, Emergen Research has segmented into the global minimally invasive biopsy technologies market on the basis of technology, therapeutic application, end use and region:

 

Technology Outlook (Revenue, USD Billion; 2017-2027)

  • Liquid Biopsy
  • Optical Biopsy
  • Brush Biopsy
  • Pigmented Lesion Assays
  • Breath Biopsy
  • Others

Therapeutic Application Outlook (Revenue, USD Billion; 2017-2027)

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Blood Cancer
  • Non-oncology Applications

End-Use Verticals Outlook (Revenue, USD Billion; 2017-2027)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Others

Regional Outlook (Revenue, USD Billion; 2017–2027)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • BENELUX
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Turkey
    • Rest of MEA

Explore Similar Reports offered by Emergen Research:

The global nutrigenomics market size reached USD 389.4 Million in 2020 and is expected to register a CAGR of 16.2% during the forecast period.

The global Sanger sequencing services market size was significantly robust in 2020 and is expected to register steady revenue CAGR over the forecast period. Increasing advancements in sequencing techniques, benefits of Sanger sequencing, and rising investments to accelerate R&D activities in genomics are key factors expected to drive market revenue growth over the forecast period.

The global whole exome sequencing (WES) market size was significantly robust in 2020 and is expected to register a steady revenue CAGR during the forecast period.

The global health data archiving market size is expected to reach USD 9.28 Billion in 2028 and register a revenue CAGR of 14.1% during the forecast period.

The global gel documentation system market size reached USD 291.5 Million in 2020 and is expected to register a revenue CAGR of 3.6% during the forecast period.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Read Our Press release@ https://www.emergenresearch.com/press-release/global-minimally-invasive-biopsy-technologies-market

 

 

 

 

 

Back to news